Obinutuzumab Efficacious for Renal Response in Lupus Nephritis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 26, 2025.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Feb. 26, 2025 -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than standard therapy alone, according to a study published online Feb. 7 in the New England Journal of Medicine. The research was published to coincide with the International Society of Nephrology annual World Congress of Nephrology, held from Feb. 6 to 9 in New Delhi.

Richard A. Furie, M.D., from Northwell Health in Great Neck, New York, and colleagues randomly assigned adults with biopsy-proven active lupus nephritis to receive obinutuzumab in one of two dose schedules or placebo (135 and 136 participants, respectively). In addition, all patients received standard therapy with mycophenolate mofetil plus oral prednisone. The primary end point was a complete renal response at week 76, defined by a urinary protein-to-creatinine ratio of less than 0.5, an estimated glomerular filtration rate of at least 85 percent of the baseline value, and no intercurrent event.

The researchers found that 46.4 and 33.1 percent of patients in the obinutuzumab and placebo groups had a complete renal response at week 76. More patients in the obinutuzumab group than the placebo group had a complete renal response at week 76 with a prednisone dose of 7.5 mg per day or lower between weeks 64 and 76 (42.7 versus 30.9 percent). A urinary protein-to-creatinine ratio lower than 0.8 without an intercurrent event was more common in the obinutuzumab group than the placebo group (55.5 versus 41.9 percent). There were no unexpected safety signals noted. More serious adverse events occurred with obinutuzumab than with placebo, and the adverse events reported were mainly infections and events related to COVID-19.

"These findings, and those from the NOBILITY trial, support the hypothesis that deep B-cell depletion with obinutuzumab is an effective treatment for patients with lupus nephritis," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including F. Hoffmann-La Roche, which manufactures obinutuzumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-02-27 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords